288 related articles for article (PubMed ID: 35214655)
1. Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies.
Reynolds CR; Tran S; Jain M; Narendran A
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214655
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy.
Guo Y; Lei K; Tang L
Front Immunol; 2018; 9():1499. PubMed ID: 30013560
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.
Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA
Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891
[TBL] [Abstract][Full Text] [Related]
4. Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.
Tang L; Zhang R; Zhang X; Yang L
Front Oncol; 2021; 11():701777. PubMed ID: 34381724
[TBL] [Abstract][Full Text] [Related]
5. Proteogenomic Platform for Identification of Tumor Specific Antigens.
Faktor J; Hernychová L; Vojtěšek B; Hupp T
Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
[TBL] [Abstract][Full Text] [Related]
6. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
7. Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.
Oosting LT; Franke K; Martin MV; Kloosterman WP; Jamieson JA; Glenn LA; de Jager MW; van Zanten J; Allersma DP; Gareb B
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890409
[TBL] [Abstract][Full Text] [Related]
8. Targeting neoantigens for cancer immunotherapy.
Zhao X; Pan X; Wang Y; Zhang Y
Biomark Res; 2021 Jul; 9(1):61. PubMed ID: 34321091
[TBL] [Abstract][Full Text] [Related]
9. [Cancer Vaccine Focused on Neoantigens].
Shindo Y; Hazama S; Nagano H
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
[TBL] [Abstract][Full Text] [Related]
10. Considerations for personalized neoantigen vaccination in Malignant glioma.
Dunn GP; Sherpa N; Manyanga J; Johanns TM
Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
[TBL] [Abstract][Full Text] [Related]
11. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
12. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
Borden ES; Buetow KH; Wilson MA; Hastings KT
Front Oncol; 2022; 12():836821. PubMed ID: 35311072
[TBL] [Abstract][Full Text] [Related]
13. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
14. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
[TBL] [Abstract][Full Text] [Related]
15. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
16. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Wirth TC; Kühnel F
Front Immunol; 2017; 8():1848. PubMed ID: 29312332
[TBL] [Abstract][Full Text] [Related]
17. SIGANEO: Similarity network with GAN enhancement for immunogenic neoepitope prediction.
Ye Y; Shen Y; Wang J; Li D; Zhu Y; Zhao Z; Pan Y; Wang Y; Liu X; Wan J
Comput Struct Biotechnol J; 2023; 21():5538-5543. PubMed ID: 38034402
[TBL] [Abstract][Full Text] [Related]
18. Current Trends in Neoantigen-Based Cancer Vaccines.
Ho SY; Chang CM; Liao HN; Chou WH; Guo CL; Yen Y; Nakamura Y; Chang WC
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986491
[TBL] [Abstract][Full Text] [Related]
19. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
20. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
